TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14722446

Group type: EXPERIMENTAL
Intervention: 10‐mg once‐daily topical regimen of miconazole nitrate mucoadhesive buccal tablet (n = 178)
Number of subjects: 357

Group type: COMPARATOR
Intervention: 400‐mg once‐daily systemic regimen of ketoconazole (n = 179)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: 10‐mg once‐daily topical regimen of miconazole nitrate mucoadhesive buccal tablet
Number of subjects: 357

Group type: COMPARATOR
Intervention: 400‐mg once‐daily systemic regimen of ketoconazole
Number of subjects: 357
Study: 11095468

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol supplementation (TES); n = 10; Estraderm, 50 microg/24 h
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (PL); n = 9
Number of subjects: 45
Study: 9200170

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam (control)
Number of subjects: 0
Study: 8250719

Group type: EXPERIMENTAL
Intervention: Hydrocortisone sodium succinate (HCSS) 5 mg hydrocortisone/kg body weight
Number of subjects: 10

Group type: COMPARATOR
Intervention: Epinephrine (0.004 mg/kg)
Number of subjects: 10
Study: 3898836

Group type: EXPERIMENTAL
Intervention: Induction therapy with carmustine, cyclophosphamide, and prednisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction therapy with melphalan and prednisone
Number of subjects: 0
Study: 28605235

Group type: EXPERIMENTAL
Intervention: Hip strengthening (resistance bands, 3 times a week for 4 weeks)
Number of subjects: 26
Study: 26867083

Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-based cognitive-behavioral treatment (iCBT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Moderated online discussion forum (Control)
Number of subjects: 124
Study: 25601789

Group type: EXPERIMENTAL
Intervention: Durable-polymer zotarolimus-eluting stent
Number of subjects: 2999

Group type: COMPARATOR
Intervention: Biodegradable-polymer biolimus-eluting stent
Number of subjects: 2999
Study: 23488876

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg alcohol
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 3.57 ml/kg energy drink (ED)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Alcohol and ED (AmED)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 28
Study: 21774589

Group type: EXPERIMENTAL
Intervention: 1,000 mg of elemental calcium with 400 IU vitamin D3
Number of subjects: 36282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study: 19179743

Group type: EXPERIMENTAL
Intervention: Ready-to-Use Therapeutic Food (RUTF)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Cereal legume-based khichri
Number of subjects: 31
Study: 16426291

Group type: EXPERIMENTAL
Intervention: Flutivate cream containing FA
Number of subjects: 24

Group type: COMPARATOR
Intervention: Betnovate cream not containing FA
Number of subjects: 24
Study: 15234130

Group type: EXPERIMENTAL
Intervention: Baseline visual acuity, contrast sensitivity, and critical print size measurements
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Drusen characteristics and focal hyperpigmentation evaluation
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: NEI‐VFQ‐25 scores
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Correlation between drusen area and focal hyperpigmentation
Number of subjects: 1052

Group type: EXPERIMENTAL
Intervention: Overall visual function assessment
Number of subjects: 1052
Study: 11246305

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) high-dose treatment (6 g on day 1, 12 g on day 2, 18 g on days 3 and 4)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) high-dose treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (mucolytic basis dosage of NAC 3 x 300 mg/day)
Number of subjects: 30
Study: 9038857

Group type: EXPERIMENTAL
Intervention: 0.025 mg rhGH/kg once daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: rhIGF-I at 0.015 mg/kg twice daily (low dose)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: rhIGF-I at 0.03 mg/kg twice daily (mid dose)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: rhIGF-I at 0.06 mg/kg twice daily (high dose)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: mid dose rhIGF-I
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: high dose rhIGF-I
Number of subjects: 14
Study: 7722967

Group type: EXPERIMENTAL
Intervention: Behavioral and psychophysiological predictors
Number of subjects: 80
Study: 2644150

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg t.i.d.)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 1138682

Group type: EXPERIMENTAL
Intervention: Norepinephrine (4%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Norepinephrine (2%, 3%, and 4%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norepinephrine with pilocarpine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Norepinephrine borate (4%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 0
Study: 30409738

Group type: EXPERIMENTAL
Intervention: 2nd generation Cryoballoon for pulmonary vein isolation (PVI)
Number of subjects: 77
Study: 28691645

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (15 minutes)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nonexercise control (rest)
Number of subjects: 22
Study: 25909710

Group type: EXPERIMENTAL
Intervention: Mesna (360 mg/m2) co-administered with doxorubicin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline co-administered with doxorubicin
Number of subjects: 32
Study: 24781527

Group type: EXPERIMENTAL
Intervention: 150 mg/day erlotinib or a body weight-adjusted dose with subsequent escalations to 200 mg/day
Number of subjects: 55
Study: 22366136

Group type: EXPERIMENTAL
Intervention: 0.5% chemically modified lignin in diet contaminated with 7.9 mg/kg ZEA
Number of subjects: 4

Group type: COMPARATOR
Intervention: Uncontaminated control diet
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Diet contaminated with 7.9 mg/kg ZEA
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 0.5% lignin in diet contaminated with 7.9 mg/kg ZEA
Number of subjects: 4
Study: 20558423

Group type: EXPERIMENTAL
Intervention: 20 ms PRP
Number of subjects: 24

Group type: COMPARATOR
Intervention: 100 ms PRP
Number of subjects: 24
Study: 18453647

Group type: EXPERIMENTAL
Intervention: Multisensory stimulation (MSS) given for 12 weeks, either 1 or 3 sessions per week.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 15696578

Group type: EXPERIMENTAL
Intervention: Etanercept (0.4 mg/kg) administered subcutaneously twice weekly for 6 months
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo administered subcutaneously twice weekly for 6 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12576241

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 222

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 222
Study: 10501986

Group type: EXPERIMENTAL
Intervention: Topical miotics (n = 28)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Without miotics (n = 24)
Number of subjects: 52
Study: 9116317

Group type: EXPERIMENTAL
Intervention: High energy intake
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Total fat and various types of fats
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Higher intakes of beta carotene or vitamin C
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Higher intake of carbohydrates and calcium
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Higher triceps skinfold thickness
Number of subjects: 676
Study: 8477278

Group type: EXPERIMENTAL
Intervention: Restrained dieters in a negative mood state
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nondieters (irrespective of restraint status)
Number of subjects: 80
Study: 3555370

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg every 8 hours)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Verapamil (drug levels higher than 150 ng/ml)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Verapamil (drug levels lower than 150 ng/ml)
Number of subjects: 109
Study: 31186155

Group type: EXPERIMENTAL
Intervention: Modified Team-Based Learning (TBL) sessions
Number of subjects: 105

Group type: COMPARATOR
Intervention: Traditional lectures
Number of subjects: 105
Study: 29042456

Group type: EXPERIMENTAL
Intervention: Corticosteroid monotherapy
Number of subjects: 162

Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Immunosuppressive combination
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Immunosuppressive regimens
Number of subjects: 162
Study: 26689579

Group type: EXPERIMENTAL
Intervention: Intradiscal Biacuplasty (IDB)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional Medical Management (CMM)
Number of subjects: 63
Study: 24935517

Group type: EXPERIMENTAL
Intervention: Midazolam and Propofol (sequential use)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 135
Study: 22322988

Group type: EXPERIMENTAL
Intervention: Right hemisphere processing enhancement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left hemisphere processing enhancement
Number of subjects: 0
Study: 20552171

Group type: EXPERIMENTAL
Intervention: TFMPP 60 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18486093

Group type: EXPERIMENTAL
Intervention: Cesarean delivery with appendectomy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard cesarean delivery
Number of subjects: 93
Study: 15917266

Group type: EXPERIMENTAL
Intervention: Extract of Cajanus cajan (Ciklavit) administered twice daily for 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo administered twice daily for 6 months
Number of subjects: 100
Study: 12692572

Group type: EXPERIMENTAL
Intervention: ACE-I (trandolapril or perindopril)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ARB (losartan or candesartan)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ACE-I
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ARB
Number of subjects: 27
Study: 10229991

Group type: EXPERIMENTAL
Intervention: Computer-based clinical decision support system (CDSS)
Number of subjects: 879

Group type: COMPARATOR
Intervention: Control group (no CDSS)
Number of subjects: 879

Group type: EXPERIMENTAL
Intervention: Intervention group (CDSS)
Number of subjects: 879
Study: 8731235

Group type: EXPERIMENTAL
Intervention: 300 mg etodolac b.i.d for three days after a 36-hour placebo washout
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50 mg indomethacin b.i.d for three days after a 36-hour placebo washout
Number of subjects: 20
Study: 8298199

Group type: EXPERIMENTAL
Intervention: ALN 10 mg daily
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: ALN 20 mg daily
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: CT 100 IU daily
Number of subjects: 286
Study: 3080510

Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg every day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 30074006

Group type: EXPERIMENTAL
Intervention: 8% arginine-calcium carbonate toothpaste (Colgate® Sensitive Pro‐Relief™) with iontophoresis
Number of subjects: 80

Group type: COMPARATOR
Intervention: 8% arginine-calcium carbonate toothpaste (Colgate® Sensitive Pro‐Relief™) without iontophoresis
Number of subjects: 80
Study: 27442155

Group type: EXPERIMENTAL
Intervention: Low-dose inhaled nitric oxide (iNO) starting at 5 parts per million, maintenance dose of 2 parts per million for ⩾7 days (n=162)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Control group (n=240)
Number of subjects: 402
Study: 24337471

Group type: EXPERIMENTAL
Intervention: Expanded School Mental Health (ESMH) treatment
Number of subjects: 307

Group type: COMPARATOR
Intervention: Matched high-risk sample (no ESMH services)
Number of subjects: 307
Study: 22985572

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.05 µg·kg(‐1)·min(‐1)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.10 µg·kg(‐1)·min(‐1)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.20 µg·kg(‐1)·min(‐1)
Number of subjects: 164

Group type: COMPARATOR
Intervention: No drug (Control group D)
Number of subjects: 164
Study: 20637962

Group type: EXPERIMENTAL
Intervention: Banana-flavored suspension
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lemon-flavored single-serving sachet
Number of subjects: 40
Study: 18718422

Group type: EXPERIMENTAL
Intervention: Upper tertile of reticulated platelets (RPs)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Larger platelet gate
Number of subjects: 90
Study: 15735373

Group type: EXPERIMENTAL
Intervention: Emergency SWL (Shockwave Lithotripsy)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Scheduled SWL (Control)
Number of subjects: 53
Study: 12606907

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 36

Group type: COMPARATOR
Intervention: Halothane anesthesia
Number of subjects: 36
Study: 10687570

Group type: EXPERIMENTAL
Intervention: Daily smoking relapse postpartum
Number of subjects: 228

Group type: COMPARATOR
Intervention: Abstinence or occasional smoking
Number of subjects: 228
Study: 9062044

Group type: EXPERIMENTAL
Intervention: Sahaja yoga practice for 6 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Exercises mimicking Sahaja yoga for 6 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (epileptic control)
Number of subjects: 32
Study: 1897811

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 200 micrograms QD
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray 100 micrograms BID
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study: 6291802

Group type: EXPERIMENTAL
Intervention: Clonidine, 0.3 mg/day orally for 3 days
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Naloxone, 0.4 mg intravenously on the third day of clonidine treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Clonidine-induced hypotension and rebound increase in blood pressure after cessation of clonidine
Number of subjects: 27
Study: 26365823

Group type: EXPERIMENTAL
Intervention: Vitamin D auxiliary rehabilitation therapy
Number of subjects: 82
Study: 28325697

Group type: EXPERIMENTAL
Intervention: sALCAM in diabetic patients with DN
Number of subjects: 107

Group type: COMPARATOR
Intervention: sALCAM in diabetic patients with normal albuminuria
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: ALCAM expression in glomeruli and tubules
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Correlation of ALCAM expression with sclerosis
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: S100B expression in glomeruli of diabetic patients
Number of subjects: 107
Study: 26179090

Group type: EXPERIMENTAL
Intervention: GSK2374697 2 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 24368086

Group type: EXPERIMENTAL
Intervention: Single vaccination with rHVT‐ND vaccine at one day of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single vaccination with rHVT‐ND vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster vaccination of rHVT‐ND vaccinated birds with conventional ND vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 23866474

Group type: EXPERIMENTAL
Intervention: Oral clonidine (5 g/kg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 19767629

Group type: EXPERIMENTAL
Intervention: Multifaceted community-based intervention
Number of subjects: 201

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 201
Study: 17513652

Group type: EXPERIMENTAL
Intervention: parecoxib 40 mg at induction, placebo at wound closure, parecoxib 40 mg 12 h after induction (pre)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: placebo at induction, parecoxib 40 mg at wound closure, parecoxib 40 mg 12 h after induction (post)
Number of subjects: 62

Group type: COMPARATOR
Intervention: placebo at induction, at wound closure, and 12 h after induction (control)
Number of subjects: 62
Study: 15378186

Group type: EXPERIMENTAL
Intervention: Intrarectal amifostine (1,500 mg in a 40-ml enema)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control (no amifostine)
Number of subjects: 67
Study: 11744585

Group type: EXPERIMENTAL
Intervention: Preemptive analgesia (multi-modal therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-agent therapy
Number of subjects: 0
Study: 9852695

Group type: EXPERIMENTAL
Intervention: Sevoflurane (S group) - slowly increased to 5% in 50% nitrous oxide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane (I group) - slowly increased to 3% in 50% nitrous oxide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol (P group) - 2.5 mg.kg‐1 with 0.2 microgram.kg‐1 fentanyl
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane (I group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol (P group)
Number of subjects: 30
Study: 8047560

Group type: EXPERIMENTAL
Intervention: Exercises in water
Number of subjects: 20

Group type: COMPARATOR
Intervention: Exercises on land
Number of subjects: 20
Study: 2648650

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 55
Study: 4712484

Group type: EXPERIMENTAL
Intervention: Intravenous atropine with propanidid
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propanidid, nitrous oxide, and halothane anaesthesia
Number of subjects: 50
Study: 30992200

Group type: EXPERIMENTAL
Intervention: Cinnamomum zeylanicum extract at 4 mg/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cinnamomum zeylanicum extract at 2 mg/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cinnamomum zeylanicum extract (various concentrations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cystone (various concentrations)
Number of subjects: 0
Study: 28435494

Group type: EXPERIMENTAL
Intervention: LUCAS mechanical chest compression device
Number of subjects: 23

Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 23
Study: 25307130

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1185

Group type: COMPARATOR
Intervention: B50 group
Number of subjects: 1185

Group type: COMPARATOR
Intervention: Other group
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1185
Study: 24088003

Group type: EXPERIMENTAL
Intervention: Radiofrequency isolation of ostia of pulmonary veins (group 1, n=31)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Radiofrequency modified mini‐maze procedure (group 2, n=30)
Number of subjects: 95

Group type: COMPARATOR
Intervention: CABG without AF elimination (control group 3, n=34)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Reveal XT devices used in 53 patients (21 in group 1, 25 in group 2, 7 in group 3)
Number of subjects: 95
Study: 22018333

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Recommended Pharmacological Treatment (RPT)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 169
Study: 18804330

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 I.U.)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 16574594

Group type: EXPERIMENTAL
Intervention: Semen specimens stored at 5 degrees C for 24 hours using the Bio-Tranz shipping system
Number of subjects: 128

Group type: COMPARATOR
Intervention: Semen specimens processed for IUI after 24 hours of storage
Number of subjects: 128
Study: 12966613

Group type: EXPERIMENTAL
Intervention: Tai chi exercise (12 forms of Sun-style tai chi) for 12 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no tai chi exercise)
Number of subjects: 72
Study: 11153860

Group type: EXPERIMENTAL
Intervention: Fast upbeat music
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Self‐selected music
Number of subjects: 27

Group type: COMPARATOR
Intervention: No music
Number of subjects: 27
Study: 9190004

Group type: EXPERIMENTAL
Intervention: Postmenopausal osteoporosis
Number of subjects: 47

Group type: COMPARATOR
Intervention: Age-matched controls for postmenopausal osteoporosis
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Glucocorticoid-induced osteoporosis
Number of subjects: 47

Group type: COMPARATOR
Intervention: Age-matched controls for glucocorticoid-induced osteoporosis
Number of subjects: 47
Study: 1340550

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subcutaneous salbutamol (0.5 mg)
Number of subjects: 20
Study: 2420347

Group type: EXPERIMENTAL
Intervention: Bilateral local infiltration with 0.25% bupivacaine plain
Number of subjects: 60
Study: 31437695

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine (standard dose)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg ketamine (low dose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 48
Study: 29794060

Group type: EXPERIMENTAL
Intervention: Bilateral deep brain stimulation (DBS) targeting the anterior limb of the internal capsule in nondiabetic patients.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Optogenetic activation of dopamine D1 receptor-expressing neurons in the nucleus accumbens in mice.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Systemic dopamine depletion in healthy subjects.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Case of a diabetes patient treated with DBS.
Number of subjects: 14
Study: 27123886

Group type: EXPERIMENTAL
Intervention: Trabeculotomy combined with cataract surgery
Number of subjects: 142